Efficacy of Anti-VEGF Agents in the Treatment of Age-Related Macular Degeneration

Size: px
Start display at page:

Download "Efficacy of Anti-VEGF Agents in the Treatment of Age-Related Macular Degeneration"

Transcription

1 Efficacy of Anti-VEGF Agents in the Treatment of Age-Related Macular Degeneration Marilita M. Moschos Abstract- Purpose: To evaluate by OCT and mf-erg the macular function in eyes with CNV due to ARMD before and after intravitreal use of bevacizumab and ranibizumab. Methods: Eighteen eyes with subfoveal CNV due to ARMD were studied before and after intravitreal use of bevacizumab with MFERG and OCT. The post follow up was three months. Also fifteen eyes with CNV due to ARMD were studied with OCT and mferg before, during and at the end of the, a year after the first injection of ranibizumab. Results: Three months after with bevacizumab, OCT showed a real resolution of the subretinal fluid. The electrical responses in the fovea and parafovea remained the same or slightly improved in some cases. After the use of ranibizumab visual acuity increases significantly by time (p=0.005). A borderline negative association between foveal thickness and time with decrease of the mean foveal thickness for one time increment was found. The retinal response density of mferg show a significant increase in ring 1, remained almost unchanged in ring 2, whereas in ring 3 there is some evidence of increase not statistically significant. Conclusion: The intravitreal use of bevacizumab may provide anatomical correlates that support the concept of disease amelioration but the functional improvement of the macula three months after is not obvious. The intravitreal use of ranibizumab may provide some anatomical and electrophysiological amelioration of the macula. However, randomized long-term clinical trials are needed to determine the potential clinical benefit of bevacizumb and ranibizumab. Keywords: Age related macular degeneration (ARMD), bevacizumab (Avastin), ranibizumab, multifocal Electroretinogram (MFERG), Optical Coherence Tomography (OCT). I. INTRODUCTION Choroidal neovascularisation (CNV) is a leading cause of loss of central vision in developed countries.[1] The neovascularisation is originated from the choroidal blood vessels and grows through Bruch s membrane usually at multiple sites into the sub-retinal pigmented epithelial space and disrupts the anatomy of the retinal pigment epithelium photoreceptors complex.[2,3,4] The important role of the vascular endothelial growth factor (VEGF) in the pathogenesis of exudative ARMD has been documented in many studies [5,6,7] and new therapeutic strategies consider the application of VEGFbinding substances to reduce the activity of VEGF and thus to prevent progression of exudative ARMD. Bevacizumab binds all biologically active forms of VEGF, as ranibizumab does. It is currently approved for use in humans but is labeled for cancer [7]. In our study we offered offlabel intravitreal use of bevacizumab to patients with CNV due to ARMD not expected to respond to conventional methods of [8]. The aim of our nonrandomized prospective study was to 190

2 record the electroretinographic changes of the foveal, parafoveal and perifoveal area by means of mferg [9] in eyes with subfoveal CNV concurrently with OCT changes before and after intravitreal use of bevacizumab of ranibizumab and to assess objectively its efficacy. II. MATERIALS and METHODS We studied 2 groups of patients Group A includes 18 eyes of 18 consecutive patients with CNV secondary to ARMD treated with off-label intravitreal bevacizumab. All eyes had large occult or minimally classic lesions. In these cases no benefit would be expected by using any alternative method of. The study protocol was approved by the local institutional review board of our hospital and all the patients signed a written consent statement particularly in the regard to the offlabel use of intravitreal use of bevacizumab. The mean age of the patients was years (range 52-84), (SD 8.31) (Table 1). Ten patients were males and eight females. Best corrected visual acuity was measured by means of standard Snellen chart at baseline, 1 month and 3 months after. The procedure was carried out in the operation theatre. Topical proparacaine hydrochloride 0.5% was applied to the ocular surface followed by preparation with 5% povidone iodine. Visual acuity and MFERG monitored the functional response to. The anatomical improvement was assessed by OCT central macular thickness measurement at 1 and 3 months after in injection. Group B includes 15 patients (15 eyes) with CNV due to ARMD were treated with intravitreal use of ranibizumab. All eyes had predominantly classic, minimal classic or occult CNV. Nine patients were female and six male with a mean age of 70.6 (SD 5.94). All eyes were injected monthly for the first 3 months, followed by doses every three months for a year with 0.3 mg of intravitreal ranibizumab. Thus during the 12-months study, a total of six ranibizumab injections were given. Intravitreal injection procedure has been described previously.[16] On presentation all patients underwent a complete ophthalmic examination, including measurement of best corrected visual acuity, fundus examination, intraocular pressure measurement, fluorescein angiography, OCT scan and mf-erg recording. At subsequent injection visits, subjects underwent a preinjection safety evaluation. OCT and mf-erg assessment was evaluated at the 1st, 3rd, 6th, 9th and 12th month after the first injection of ranibizumab. Best corrected visual acuity was measured by means of LogMar equivalent at baseline, 1, 3, 6, 9 and 12 months after the first injection of ranibizumab. Optical Coherence Tomography (OCT) OCT examination was performed with the OCT model (Carl Zeiss Meditec, Stratus OCT). The retinal mapping software was used, calculating the averaged retinal thickness of the central ring. All eyes were scanned in a radial spoke pattern centered on the foveola with scan length of 6mm. Multifocal-ERG For the recording of the mf-erg, the EP model (Tomey, Nagoya, Japan) was used and the recording protocol followed was according to the ISCEV guidelines for basic mf-erg. Statistical analysis Quartiles, mean and standard deviation were calculated in each time period in order to describe the distribution of amplitude, latency, foveal thickness and visual acuity. Linear mixed effects models were used to analyze the data. Differences in longitudinal amplitude and latency data over time were evaluated among foveal (ring1), parafoveal (ring 2) and perifoveal (ring 3) area. The interaction term (type of ring*time) was included to consider differential effects in the rate of change over time in each ring. Foveal thickness and visual acuity were measured only in the foveal area (ring 1). Kolmogorov- 191

3 Smirnov test evaluated the assumption of normality. We tested for quadratic term of time, but it was not found significant in none of the statistical models. Restricted likelihood (REML) was used for maximization. All statistical tests were two sided; p-value<0.05 was considered statistically significant. The analyses were conducted with Stata statistical software (version 10) and graphs with MLwiN. III. RESULTS Table 1 shows the changes of VA during the 3 months follow-up period after the injection with bevacizumab. No significant difference was found between VA at baseline and 3 months after (P=0.2261) (Table 1). Table 2 shows the changes of foveal thickness during the 3 months follow-up period after with bevacizumab. Statistical analysis revealed an extremely significant difference between foveal thickness at baseline and 1 month after (P<0.001). No difference was found 3 months after (P=0.0592). It is interesting that 3 months after, in 8 cases the foveal thickness (case no 1, 9, 10, 11, 12, 14, 15, 16 and 17) was lower than before, in 4 cases (case no 5, 8, 13 and 18) was higher and in the remaining 5 cases (case no 2, 3, 4, 6 and 7) remained almost unchanged. Concerning the mf-erg changes in area 1 no difference was found between baseline and 3 months (P=0.1285) (Table 2). Statistical analysis revealed a very significant difference between retinal response density of area 2 at baseline and 1 month after (P<0.01). This difference remained significant 3 months after (P<0.05) (Table 2 and Fig 1). It should be stressed that 3 months after, the retinal response density of area 1 improved more than 1nV/deg² in 8 cases (case no 4, 5, 9, 10, 13, 15 and 17), decreased in 2 cases (case no 8 and 12) and remained almost stable in the remaining 8 cases. The retinal response density of area 2 recorded by MFERG improved of more than 1nV/deg² in 4 cases (case no 3, 5, 7 and 8) and remained almost unchanged in the remaining 14 cases. On the other hand a total of 15 patients (15 eyes) treated with ranibizumab were included in the study. Figure 2 shows graphical presentations of the mean values of retinal response density (Figure 2A), latency (Figure 2B), foveal thickness (Figure 2C) and VA (Figure 2D) in each time measurement (Figure 3, 4). Several models of the linear mixed effects analysis are presented in Table 3. In Model 1 retinal response density was considered as the outcome variable whereas time and ring as the explanatory ones. There was a highly significant interaction between ring and time, indicating differences in the rate of change of amplitude over time among the three rings. Specifically, one time unit increase was found to increase significantly the mean retinal response density in ring1 by 5.13 nv/deg 2 (95% CI: 2.45, 7.80). However, mean retinal response density remained almost unchanged over time in ring 2, whereas for ring 3, there was some evidence for increase over time but the result was of borderline significance (p=0.063). In Model 2 latency was the outcome variable whereas time and ring the explanatory variables. At baseline measurement the mean levels of latency were not found to differ significantly among ring 1, ring 2 and ring 3. Time did not seem to have any effect in latency levels with mean latency remaining almost unchanged throughout the twelve months of the period in all the three rings. With respect to foveal thickness which was measured by OCT, the linear mixed effects analysis (Model 3, Table 3) showed a borderline inverse association between foveal thickness and time (p=0.065) with a decrease of mean foveal thickness by 8.46 µm (95% CI: , 0.52) for one time unit increase. Lastly, according to Model 4 (Table 3), a highly significant time effect was identified, with mean visual acuity increasing significantly by time (p=0.005). 192

4 Concerning retinal response density, its significant positive association with time remained. Amplitude was not found to be associated with foveal thickness (p=0.887) whereas a borderline positive association was identified between amplitude and visual acuity (OR: , 95% CI: , 0.63). Concerning latency, its relationship with time remained statistically non-significant even after adjustment for foveal thickness and visual acuity. Foveal thickness and visual acuity seemed to be unrelated to latency. Visual acuity, after adjustment for foveal thickness, increased significantly by time. However foveal thickness was not found to be associated with visual acuity (p=0.482). IV. DISCUSSION The of choroidal neovasularization in ARMD has changed enormously during the last decade. While 10 years there was only Argon laser coagulation and later photodynamic therapy with verteporfin, today we have several options for CNV.[1] Results from PIER study indicate that ranibizumab administered on a schedule of monthly dosing for three months followed by quarterly dosing provides significant visual acuity benefit to patients with all angiographic subtypes of CNV. Unfortunately, there are no data available at six and nine months to allow assessment of duration of action of ranibizumab in the individual subjects and the temporal association with retinal thickness. In this retrospective study 18 eyes with CNV due to ARMD were treated with intravitreal bevacizumab. Our results show that there are anatomical correlates to support the concept of disease improvement. This is mainly the decrease of macular thickness as measured by OCT in an extremely significant degree (P<0.001) the first month after. On the contrary the mean visual acuity improved only by 0.03 the first month after and by 0.02 three months after. Also the MFERG improvement did not follow the decrease of macular thickness and is significant the first month after (P<0.05). However MFERG results, three months after, show a little rise of the electrical activity of area 2 (P<0.05), which may be attributed to the decrease of the macular edema more than to the improvement of the macular function [9, 10]. Our results from the intravitreal use of ranibizumab show a significant increase of the visual acuity and the retinal response density of the foveal area (ring1) during, whereas in ring 2 and 3 the retinal response density remained almost unchanged. Also, the latency remained unchanged during. Concerning with the foveal thickness a borderline non statistically significant decrease was identified. Finally, visual acuity and retinal response density of the foveal area seemed to be unrelated with foveal thickness. This may be explained by the fact that the macular edema is only a parameter that may affect visual acuity and the electrical activity of the macula. Consequently, increase or decrease of macular thickness does not necessarily reflect the course of the visual acuity as supported.[11] Atrophy of the retina, particularly of the photoreceptors, atrophy of the pigment epithelium and scarring are all unmeasured parameters which influence vision. While anti-vegf s are revolutionary, the frequency of use of the drugs still needs to be determined. Two previous studies investigated the effects of anti-vegf (bevacizumab) on retinal function by means of mf-erg in ARMD patients before and after intravitreal use of bevacizumab.[10] They found that neuroretinal function did not change in most of the patients compared to baseline values. Feigl s preliminary results in a small number of patients receiving ranibizumab confirm the above mentioned studies.[12] However we consider that randomized longterm clinical trials are needed to determine more accurately the potential clinical benefit of intravitreal anti-vegf. REFERENCES 193

5 1. Kroll P, Meyer CH (2006) Which is best for AMD patients. Br J Ophthalmol. 90: Chang TS, Freund KB, de la Cruz Z, Yannouzi LA, Green WR (1994) Clinicopathological correlation of choroidal neovascularization demonstrated by indocyanine green angiography in a patient with retention of good vision for almost four years. Retina. 14: Green WR, Wilson DJ (1996) Choroidal neovascularisation. Ophthalmology. 93: Green WR, Ehger C (1993) Age related macular degeneration histopathologic studies. The 1992 Lorenz E. Zimmerman Lecture. Ophthalmology. 100: Ambati J, Ambati BK, Yoo SH, Lanchulev S, Adamis AP (2003) Agerelated macular degeneration: etiology, pathogenesis and therapeutic strategies. Surv Ophthalmol. 48: Zarbin MA (2004) Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol. 122: Adamis AP, Shima DT (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina. 25: Avery RL, Pieramici DJ, Rabena MD et al (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 113: e5. 9. Sutter EE, Tram D (1992) The field topography of ERG components in man. I. The photopic luminance response. VBision res. 32: Moschos MM, Brouzas D, Apostolopoulos M, Koutsandrea Chr, 11. Loukianou E, Moschos M (2007) Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal ERG and OCT study. Doc Ophthalmologica. 114: Lipski A, Bornfeld N, Jurklies B (2007) Multifocal electroretinography in patients with exudative AMD and intravitreal with pegaptamib sodium. Retina. 27: Feigl B, Greaves A, Brown B (2007) Functional outcome after multiple s with ranibizumab in neovascular age-related macular degeneration beyond visual acuity. Clin Ophtalmology

6 Table 1. Clinical data of patients with CNV due to ARMD before, 1 and 3 months after with bevacizumab. No Age VA* before VA* 1 month after Mean value SD *Visual VA* 3 months after acuity 195

7 Table 2. OCT and MFERG recordings of area 1 and 2 before, 1 month and 3 months after with bevacizumab. The mean foveal thickness measured by OCT is expressed in µm. The retinal response densities measured by MFERG are expressed in nv/deg². No Before 1 month after 3 months after Before 1 month after 3 months after OCT OCT OCT Area 1 Area 2 Area 1 Area 2 Area 1 Area Average STDEV

8 Figure 2. Mean values in the foveal area (ring 1) in each time measurement* for: (A) amplitude of mfvep, (B) latency of mfvep, (C) foveal thickness, and (D) visual acuity of patients treated with ranibizumab Figure A Figure B Figure C Figure D *Time measurement: 1: baseline 2: 1 month after first 3: 3 months after first 4: 6 months after first 5: 9 months after first 6: 12 months after first 197

9 Table 3: Linear mixed effects analysis for the association between over time and amplitude (Model 1), latency (Model 2), foveal thickness (Model 3) and visual acuity (Model 4) of patients treated with ranibizumab Category or Increment Coefficient 95% CI P-value Model 1: Amplitude Intercept Ring (88.41, ) - Ring (60.81, 91.98) Ring (36.69, 67.86) < Time 1 time unit increase in Ring (2.45, 7.80) - 1 time unit increase in Ring (-2.17, 3.17) time unit increase in Ring (-0.78, 4.57) Model 2: Latency Intercept Ring (40.29, 44.99) - Ring (38.68, 43.38) Ring (39.36, 44.06) Time 1 time unit increase in Ring (-0.38, 0.38) - 1 time unit increase in Ring (-0.55, 0.21) time unit increase in Ring (-0.49, 0.27) Model 3: Foveal thickness Intercept (363.12, ) - Time 1 time unit increase (-17.44, 0.52) Model 4: Visual acuity Intercept 0.23 (0.17, 0.29) - Time 1 time unit increase (-0.009, ) Ring 1 is the reference group. All P-values derived from the comparison of each category with the reference group. 198

10 Proceedings of the World Medical Conference Figure 1. MFERG of case 2, at presentation (A) and 3 months later (B). The 3-dimension topographic plot of MF-ERG 3 months after remains pathological and the ERG traces in area 1 and 2 do not show any amelioration. Figure 3. OCT recordings, 3-dimension topographic plot and mf-erg traces dimension topographic plot of a case at presentation (A), 6 months (B) and 1 year after (C) with ranibizumab. The pre OCT showed an increase of central retinal thickness and mf-erg revealed a decrease of electrical activity of the fovea and perifovea area. At the end of the follow-up period (C) the retinal thickness of the fovea was decreased and the mf-erg was ameliorated. 199

11 Figure 4. OCT recordings, 3-dimension topographic plot and mf-erg traces dimension topographic plot of a case at presentation (A), 6 months (B) and 1 year after (C) with ranibizumab. The pre OCT showed an increase of central retinal thickness and a decrease of electrical activity of the fovea and perifovea area. At the end of the follow-up period (C) the retinal thickness of the fovea was still increased and the mf-erg revealed a craterlike depression of the foveal and parafoveal area.. 200

International Journal of Health Sciences and Research ISSN:

International Journal of Health Sciences and Research   ISSN: International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article A Multivariate Analysis of Intravitreal Injection of Anti-VEGF Bevacizumab in the Treatment

More information

A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration

A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration Clinical and Economic Impact Omesh P. Gupta, MD, MBA, Gary Shienbaum, MD, Avni H. Patel, MD, Christopher Fecarotta,

More information

Focal Macular Electroretinograms after Intravitreal Injections of Bevacizumab for Age-Related Macular Degeneration

Focal Macular Electroretinograms after Intravitreal Injections of Bevacizumab for Age-Related Macular Degeneration Retina Focal Macular Electroretinograms after Intravitreal s of Bevacizumab for Age-Related Macular Degeneration Eiji Iwata, Shinji Ueno, Kohei Ishikawa, Yasuki Ito, Ruka Uetani, Chang-Hua Piao, Mineo

More information

Clinical Trials Related to Age Related Macular Degeneration

Clinical Trials Related to Age Related Macular Degeneration Clinical Trials Related to Age Related Macular Degeneration Kirti Singh MD, DNB, FRCS Kirti Singh MD, DNB, FRCS, Pooja Jain MBBS, Nitasha Ahir MBBS, Divya Jain MD, DNB Guru Nanak Eye Centre, Maulana Azad

More information

SUMMARY. Heather Casparis, MD,* and Neil M. Bressler, MD MARINA AND ANCHOR

SUMMARY. Heather Casparis, MD,* and Neil M. Bressler, MD MARINA AND ANCHOR The following are summaries of selected presentations and posters from the American Society of Retina Specialists and European VitreoRetinal Society Annual Meeting held September 9 13, 2006, in Cannes,

More information

Although photocoagulation and photodynamic PROCEEDINGS PEGAPTANIB SODIUM FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION *

Although photocoagulation and photodynamic PROCEEDINGS PEGAPTANIB SODIUM FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION * PEGAPTANIB SODIUM FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION Evangelos S. Gragoudas, MD ABSTRACT In December 24, the US Food and Drug Administration (FDA) approved pegaptanib sodium. Pegaptanib

More information

Efficacy of intravitreal bevacizumab (Avastin TM ) for shortterm treatment of diabetic macular edema

Efficacy of intravitreal bevacizumab (Avastin TM ) for shortterm treatment of diabetic macular edema 111 ORIGINAL Efficacy of intravitreal bevacizumab (Avastin TM ) for shortterm treatment of diabetic macular edema Toshihiko Nagasawa, Takeshi Naito, Shingo Matsushita, Hiroyuki Sato, Takashi Katome, and

More information

Risk factors of a reduced response to ranibizumab treatment for neovascular age-related macular degeneration evaluation in a clinical setting

Risk factors of a reduced response to ranibizumab treatment for neovascular age-related macular degeneration evaluation in a clinical setting Korb et al. BMC Ophthalmology 2013, 13:84 RESEARCH ARTICLE Open Access Risk factors of a reduced response to ranibizumab treatment for neovascular age-related macular degeneration evaluation in a clinical

More information

Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration.

Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration. Thomas Jefferson University Jefferson Digital Commons Wills Eye Institute Papers Wills Eye Institute 4-1-2008 Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related

More information

A prospective nonrandomized clinical study on exudative age related macular degeneration

A prospective nonrandomized clinical study on exudative age related macular degeneration Original Article A prospective nonrandomized clinical study on exudative age related macular degeneration Ayakutty Muni Raja, Siddharam Janti, Charanya Chendilnathan, Adnan Matheen Department of Ophthalmology,

More information

Macular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments Trials

Macular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments Trials Macular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments Trials Glenn J. Jaffe, MD, 1 Daniel F. Martin, MD, 2 Cynthia A. Toth, MD, 1 Ebenezer Daniel, MPH, PhD,

More information

Retinal Pigment Epithelial Tears (Rips) in the ERA of Anti Vegf - When and Why?

Retinal Pigment Epithelial Tears (Rips) in the ERA of Anti Vegf - When and Why? Original Article Retinal Pigment Epithelial Tears (Rips) in the ERA of Anti Vegf - When and Why? Dr Sreelekha S. MS, DNB, DO, FRCS, Dr Manoj Soman DNB, FICO, FRCS, Dr. Unni Nair MS, FRCS, Dr. Ruminder

More information

RETINAL VENOUS OCCLUSIVE DISEASE IS PROBABLY

RETINAL VENOUS OCCLUSIVE DISEASE IS PROBABLY Clinical, Anatomic, and Electrophysiologic Evaluation Following Intravitreal Bevacizumab for Macular Edema in Retinal Vein Occlusion SIVAKAMI A. PAI, ROHIT SHETTY, PRIYA B. VIJAYAN, VENKATASUBRAMANIAM

More information

International Journal of Basic and Applied Physiology

International Journal of Basic and Applied Physiology Multifocal Electroretinography in Assessment Of Diseases Of Posterior Pole Of Retina JagdeepKaur S. Dani*, Mitesh M. Sinha**, Archana H. Patel**, Anju B. Mehta ***, Geeta B. Nair**** *Associate Professor,

More information

FEP Medical Policy Manual

FEP Medical Policy Manual FEP Medical Policy Manual Last Review: September 2016 Next Review: September 2017 Related Policies 9.03.20 Intraocular Radiation Therapy for Age-Related Macular Degeneration Photodynamic Therapy for Choroidal

More information

Retina Conference. Janelle Fassbender, MD, PhD University of Louisville Department of Ophthalmology and Visual Sciences 09/04/2014

Retina Conference. Janelle Fassbender, MD, PhD University of Louisville Department of Ophthalmology and Visual Sciences 09/04/2014 Retina Conference Janelle Fassbender, MD, PhD University of Louisville Department of Ophthalmology and Visual Sciences 09/04/2014 Subjective CC/HPI: 64 year old Caucasian female referred by outside ophthalmologist

More information

AGE-RELATED MACULAR DEGENERATION (AMD) IS A

AGE-RELATED MACULAR DEGENERATION (AMD) IS A Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-related Macular Degeneration ZIAD F. BASHSHUR, MD, ALI BAZARBACHI, MD, ALEXANDRE SCHAKAL, MD, ZEINA A. HADDAD, MD, CHRISTELLE

More information

Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion

Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion ORIGINAL RESEARCH Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion Juan Carlos Mesa Gutiérrez Luis Arias Barquet Josep Maria Caminal Mitjana Sergi

More information

Systemic bevacizumab (Avastin) therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-Study

Systemic bevacizumab (Avastin) therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-Study 1 Department of Ophthalmology, The Ludwig Boltzmann Institute for Retinology and Biomicroscopic Lasersurgery, Rudolf Foundation Clinic, Vienna, Austria; 2 Department of Internal Medicine, Oncology, Rudolf

More information

Anti VEGF Agents in Retinal Disorders Current Scenario

Anti VEGF Agents in Retinal Disorders Current Scenario Retina Anti VEGF Agents in Retinal Disorders Current Scenario Charu Gupta MS Charu Gupta MS, Cyrus M. Shroff MD Shroff Eye Centre, New Delhi T is a group of proteins involved in the regulation of angiogenesis,

More information

Photodynamic Therapy for Choroidal Neovascularization

Photodynamic Therapy for Choroidal Neovascularization Photodynamic Therapy for Choroidal Neovascularization Policy Number: 9.03.08 Last Review: 10/2014 Origination: 10/2000 Next Review: 10/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will

More information

EFFICACY OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN RETINAL DISORDER FOR BETTER VISUAL ACUITY

EFFICACY OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN RETINAL DISORDER FOR BETTER VISUAL ACUITY EFFICACY OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN RETINAL DISORDER FOR BETTER VISUAL ACUITY Diwakar chaudhary *1, 2, Hu shuqiong, Long Yuan and Xiong kun 1 Yangtze University, 1 Nanhuan Road

More information

HHS Public Access Author manuscript Ophthalmic Surg Lasers Imaging Retina. Author manuscript; available in PMC 2016 January 14.

HHS Public Access Author manuscript Ophthalmic Surg Lasers Imaging Retina. Author manuscript; available in PMC 2016 January 14. High-Speed Ultrahigh-Resolution OCT of Bruch s Membrane in Membranoproliferative Glomerulonephritis Type 2 Mehreen Adhi, MD, Sarah P. Read, MD, PhD, Jonathan J. Liu, PhD, James G. Fujimoto, PhD, and Jay

More information

Abstract Aims To analyse the histopathology of classic and occult choroidal neovascular membrane surgical specimens in age

Abstract Aims To analyse the histopathology of classic and occult choroidal neovascular membrane surgical specimens in age Br J Ophthalmol 2000;84:239 243 239 ORIGINAL ARTICLES Clinical science Clinicopathological correlation in exudative age related macular degeneration: histological diverentiation between classic and occult

More information

ZEISS AngioPlex OCT Angiography. Clinical Case Reports

ZEISS AngioPlex OCT Angiography. Clinical Case Reports Clinical Case Reports Proliferative Diabetic Retinopathy (PDR) Case Report 969 PROLIFERATIVE DIABETIC RETINOPATHY 1 1-year-old diabetic female presents for follow-up of proliferative diabetic retinopathy

More information

Digital Journal of Ophthalmology Digital Journal of Ophthalmology. Abstract

Digital Journal of Ophthalmology Digital Journal of Ophthalmology. Abstract Original Articles Combined intravitreal ranibizumab and verteporfin photodynamic therapy versus ranibizumab alone for the treatment of age-related macular degeneration Rosalia Giustolisi, MD, Nicoletta

More information

Andrew J. Barkmeier, MD; Benjamin P. Nicholson, MA; Levent Akduman, MD

Andrew J. Barkmeier, MD; Benjamin P. Nicholson, MA; Levent Akduman, MD c l i n i c a l s c i e n c e Effectiveness of Laser Photocoagulation in Clinically Significant Macular Edema With Focal Versus Diffuse Parafoveal Thickening on Optical Coherence Tomography Andrew J. Barkmeier,

More information

Instudies of vascular endothelial growth factor

Instudies of vascular endothelial growth factor MONITORING THERAPEUTIC EFFICACY IN THE ANTI-VEGF ERA* SriniVas R. Sadda, MD ABSTRACT One of the most important questions with vascular endothelial growth factor (VEGF) inhibitors for age-related macular

More information

NIH Public Access Author Manuscript JAMA Ophthalmol. Author manuscript; available in PMC 2013 September 10.

NIH Public Access Author Manuscript JAMA Ophthalmol. Author manuscript; available in PMC 2013 September 10. NIH Public Access Author Manuscript Published in final edited form as: JAMA Ophthalmol. 2013 May ; 131(5): 693 694. doi:10.1001/jamaophthalmol.2013.692. Effect of Intravitreous Anti Vascular Endothelial

More information

Department of Ophthalmology, Kangnam Sacred Heart Hospital, College of Medicine, Hallym University, Seoul, Korea

Department of Ophthalmology, Kangnam Sacred Heart Hospital, College of Medicine, Hallym University, Seoul, Korea Department of Ophthalmology, Kangnam Sacred Heart Hospital, College of Medicine, Hallym University, Seoul, Korea Purpose: To investigate the factors that affect final vision following photodynamic therapy

More information

Photodynamic Therapy for Treatment of Subfoveal Choroidal Neovascularization in Exudative Age-Related Macular Degeneration

Photodynamic Therapy for Treatment of Subfoveal Choroidal Neovascularization in Exudative Age-Related Macular Degeneration Clinical Medicine Journal Vol. 4, No. 4, 2018, pp. 60-66 http://www.aiscience.org/journal/cmj ISSN: 2381-7631 (Print); ISSN: 2381-764X (Online) Photodynamic Therapy for Treatment of Subfoveal Choroidal

More information

Effectiveness of Ranibizumab for Neovascular Age-related Macular Degeneration using Clinician Determined Retreatment Strategy

Effectiveness of Ranibizumab for Neovascular Age-related Macular Degeneration using Clinician Determined Retreatment Strategy Effectiveness of Ranibizumab for Neovascular Age-related Macular Degeneration using Clinician Determined Retreatment Strategy Anupma Kumar, Jayashree N Sahni, Alexandros N Stangos, Claudio Campa, Simon

More information

Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment

Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment 9:30 AM Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment Lee Jampol, MD OBJECTIVE To assess subsequent visual and anatomic outcomes of eyes with

More information

CENTRAL SEROUS CHORIORETINOPATHY (CSC) IS

CENTRAL SEROUS CHORIORETINOPATHY (CSC) IS Association Between the Efficacy of Half-Dose Photodynamic Therapy With Indocyanine Green Angiography and Optical Coherence Tomography Findings in the Treatment of Central Serous Chorioretinopathy MASSIMO

More information

Five-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration: Real Life Clinical Experience

Five-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration: Real Life Clinical Experience pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2017;31(5):424-430 https://doi.org/10.3341/kjo.2016.0125 Original Article Five-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration:

More information

Department of Ophthalmology, Kim s Eye Hospital, Konyang University College of Medicine, Seoul, Korea 2

Department of Ophthalmology, Kim s Eye Hospital, Konyang University College of Medicine, Seoul, Korea 2 pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2015;29(5):315-324 http://dx.doi.org/10.3341/kjo.2015.29.5.315 Original Article Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related

More information

Subgroup Analysis of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular Degeneration

Subgroup Analysis of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular Degeneration Subgroup Analysis of the MARINA Study of in Neovascular Age-Related Macular Degeneration David S. Boyer, MD, 1 Andrew N. Antoszyk, MD, 2 Carl C. Awh, MD, 3 Robert B. Bhisitkul, MD, PhD, 4 Howard Shapiro,

More information

These issues are covered in more detail below.

These issues are covered in more detail below. 26.3.07 Comments from Novartis on the Assessment Report for the Health Technology Appraisal of Pegaptinib and Ranibizumab for the treatment of age-related macular degeneration In general we feel that the

More information

Assessment of macular function by multifocal electroretinogram before and after macular hole surgery

Assessment of macular function by multifocal electroretinogram before and after macular hole surgery 420 Department of Ophthalmology, Gunma University School of Medicine, Japan Y-J Si S Kishi K Aoyagi Correspondence to: Ying-Jie Si, MD, Department of Ophthalmology, Gunma University School of Medicine,

More information

Intravitreal Injection of Ranibizumab for Recovery of Macular Function in Eyes With Subfoveal Polypoidal Choroidal Vasculopathy

Intravitreal Injection of Ranibizumab for Recovery of Macular Function in Eyes With Subfoveal Polypoidal Choroidal Vasculopathy Retina Intravitreal Injection of Ranibizumab for Recovery of Macular Function in Eyes With Subfoveal Polypoidal Choroidal Vasculopathy Ken Ogino, Akitaka Tsujikawa, Kenji Yamashiro, Sotaro Ooto, Akio Oishi,

More information

Description. Section: Other Effective Date: July 15, Subsection: Vision Original Policy Date: December 7, 2011 Subject: Page: 1 of 23

Description. Section: Other Effective Date: July 15, Subsection: Vision Original Policy Date: December 7, 2011 Subject: Page: 1 of 23 Last Review Status/Date: June 2015 Page: 1 of 23 Description Photodynamic therapy (PDT) is a treatment modality designed to selectively occlude ocular choroidal neovascular tissue. The therapy is a 2-step

More information

OCT and muti-focal ERG findings in spontaneous closure of bilateral traumatic macular holes

OCT and muti-focal ERG findings in spontaneous closure of bilateral traumatic macular holes Doc Ophthalmol (2008) 116:159 164 DOI 10.1007/s10633-008-9113-1 CASE REPORT OCT and muti-focal ERG findings in spontaneous closure of bilateral traumatic macular holes Hongling Chen Æ Mingzhi Zhang Æ Shizhou

More information

Despite our growing knowledge of the

Despite our growing knowledge of the OVERVIEW OF AVAILABLE TREATMENTS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION * Carl D. Regillo, MD ABSTRACT Although potential treatments for neovascular age-related macular degeneration represent

More information

Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema

Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema Doc Ophthalmol (2008) 116:129 135 DOI 10.1007/s10633-007-9090-9 ORIGINAL RESEARCH ARTICLE Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab

More information

Ophthalmology Macular Pathways

Ophthalmology Macular Pathways Ophthalmology Macular Pathways Age related Macular Degeneration Diabetic Macular Oedema Macular Oedema secondary to Central Retinal Macular Oedema secondary to Branch Retinal CNV associated with pathological

More information

Clinically Significant Macular Edema (CSME)

Clinically Significant Macular Edema (CSME) Clinically Significant Macular Edema (CSME) 1 Clinically Significant Macular Edema (CSME) Sadrina T. Shaw OMT I Student July 26, 2014 Advisor: Dr. Uwaydat Clinically Significant Macular Edema (CSME) 2

More information

NEOVASCULAR AGE-RELATED MACULAR DEGENERation

NEOVASCULAR AGE-RELATED MACULAR DEGENERation Randomized, Double-Masked, -Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2 PREMA ABRAHAM, HUIBIN YUE, AND LAURA WILSON PURPOSE: To evaluate efficacy

More information

Use of Aflibercept in cases of recurrent or refractory neovascular AMD previously treated with other antiangiogenic drug: anatomo-functional outcomes

Use of Aflibercept in cases of recurrent or refractory neovascular AMD previously treated with other antiangiogenic drug: anatomo-functional outcomes Use of Aflibercept in cases of recurrent or refractory neovascular AMD previously treated with other antiangiogenic drug: anatomo-functional outcomes Daniel E. Charles, MD, Martin Charles, MD, Gisela Jelusich,

More information

IQ 532 Micropulse Green Laser treatment for Refractory Chronic Central Serous Retinopathy

IQ 532 Micropulse Green Laser treatment for Refractory Chronic Central Serous Retinopathy Cronicon OPEN ACCESS EC OPHTHALMOLOGY Case Report IQ 532 Micropulse Green Laser treatment for Refractory Chronic Central Serous Retinopathy Fawwaz Al Mamoori* Medical Retina Department, Eye Specialty Hospital,

More information

Intraocular Radiation Therapy for Age-Related Macular Degeneration

Intraocular Radiation Therapy for Age-Related Macular Degeneration Medical Policy Manual Medicine, Policy No. 134 Intraocular Radiation Therapy for Age-Related Macular Degeneration Next Review: April 2019 Last Review: June 2018 Effective: August 1, 2018 IMPORTANT REMINDER

More information

Citation. As Published Publisher. Version

Citation. As Published Publisher. Version Effect of Intravitreous Anti Vascular Endothelial Growth Factor Therapy on Choroidal Thickness in Neovascular Age-Related Macular Degeneration Using Spectral-Domain The MIT Faculty has made this article

More information

EPIRETINAL MEMBRANES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Effect on Outcomes of Anti-vascular Endothelial Growth Factor Therapy

EPIRETINAL MEMBRANES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Effect on Outcomes of Anti-vascular Endothelial Growth Factor Therapy EPIRETINAL MEMBRANES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION Effect on Outcomes of Anti-vascular Endothelial Growth Factor Therapy EMINE ESRA KARACA, MD,* BURÇIN KEPEZ YILDIZ, MD, MEHMET ÖZGÜR

More information

Stabilization of visual acuity with photodynamic therapy in eyes with chorioretinal anastomoses

Stabilization of visual acuity with photodynamic therapy in eyes with chorioretinal anastomoses Graefe s Arch Clin Exp Ophthalmol (2004) 242:368 376 CLINICAL INVESTIGATION DOI 10.1007/s00417-003-0844-0 Rufino M. Silva José R. Faria de Abreu António Travassos José G. Cunha-Vaz Stabilization of visual

More information

NIH Public Access Author Manuscript Ophthalmic Surg Lasers Imaging Retina. Author manuscript; available in PMC 2014 June 24.

NIH Public Access Author Manuscript Ophthalmic Surg Lasers Imaging Retina. Author manuscript; available in PMC 2014 June 24. NIH Public Access Author Manuscript Published in final edited form as: Ophthalmic Surg Lasers Imaging Retina. 2014 ; 45(1): 32 37. doi:10.3928/23258160-20131220-04. Analysis of the Short Term Change in

More information

연령연관황반변성에서망막혈관종성증식과동반된망막색소상피박리의임상양상과일차적인광역학치료의결과

연령연관황반변성에서망막혈관종성증식과동반된망막색소상피박리의임상양상과일차적인광역학치료의결과 연령연관황반변성에서망막혈관종성증식과동반된망막색소상피박리의임상양상과일차적인광역학치료의결과 40 Table. Clinical characteristics and results of patients undergoing photodynamic therapy for retinal angiomatous proliferation Patients No. Age/ sex Eye

More information

Anti-VEGF drugs & CATT Results. in AMD. Apollo Hospitals, Hyderabad. Mallika Goyal, MD

Anti-VEGF drugs & CATT Results. in AMD. Apollo Hospitals, Hyderabad. Mallika Goyal, MD Anti-VEGF drugs & CATT Results in AMD Mallika Goyal, MD Apollo Hospitals, Hyderabad Vascular Endothelial Growth Factor Napoleone Ferrara at Genentech 1989 identified & cloned the gene Protein that causes

More information

Michael P. Blair, MD Retina Consultants, Ltd Libertyville/Des Plaines, Illinois Clinical Associate University of Chicago 17 October 2015

Michael P. Blair, MD Retina Consultants, Ltd Libertyville/Des Plaines, Illinois Clinical Associate University of Chicago 17 October 2015 Michael P. Blair, MD Retina Consultants, Ltd Libertyville/Des Plaines, Illinois Clinical Associate University of Chicago 17 October 2015 So What Parts of the Eye Retina are Affected by VHL Neural tissue

More information

R&M Solutions

R&M Solutions Mohamed Hosny El-Bradey, MD., Assistant Professor of Ophthalmology, Tanta University. Wael El Haig, MD., Professor of Ophthalmology. Zagazeeg University. 1 Myopic CNV is considered the most common vision

More information

Management of Neovascular AMD

Management of Neovascular AMD Kapusta AMD Part 1 Management of Neovascular AMD Dr. Michael A. Kapusta, MD, FRCSC Ophthalmologist in Chief Jewish General Hospital Vitreoretinal Surgeon 1 FINANCIAL DISCLOSURES Consulting honoraria Bayer,

More information

Management of Acute Submacular Hemorrhage with Intravitreal Injection of Tenecteplase, Anti-vascular Endothelial Growth Factor and Gas

Management of Acute Submacular Hemorrhage with Intravitreal Injection of Tenecteplase, Anti-vascular Endothelial Growth Factor and Gas pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2016;30(3):192-197 http://dx.doi.org/10.3341/kjo.2016.30.3.192 Original Article Management of Acute Submacular Hemorrhage with Intravitreal Injection

More information

We know diabetes is a common and growing problem as well as the leading cause

We know diabetes is a common and growing problem as well as the leading cause ebook A GAME-CHANGER IN DIABETIC RETINOPATHY Early diagnosis and management guidance using objective, functional vision testing. by STEVEN M. SILVERSTEIN, MD We know diabetes is a common and growing problem

More information

MONTHLY ADMINISTERED INTRAVITREOUS PHARmacotherapy

MONTHLY ADMINISTERED INTRAVITREOUS PHARmacotherapy Polypoidal Choroidal Vasculopathy Masquerading as Neovascular Age-Related Macular Degeneration Refractory to Ranibizumab ALEXANDROS N. STANGOS, JAGDEEP SINGH GANDHI, JAYASHREE NAIR-SAHNI, HEINRICH HEIMANN,

More information

Schatz, Patrik; Skarin, Angelika; Lavaque, Alejandro J; Lima, Luiz H; Arevalo, Jose Fernando

Schatz, Patrik; Skarin, Angelika; Lavaque, Alejandro J; Lima, Luiz H; Arevalo, Jose Fernando Preservation of macular structure and function after intravitreal aflibercept for choroidal neovascularization associated with serpiginous choroiditis. Schatz, Patrik; Skarin, Angelika; Lavaque, Alejandro

More information

Optical Coherence Tomography Monitoring Strategies for A-VEGF Treated Age-Related Macular Degeneration: An Evidence-Based Analysis

Optical Coherence Tomography Monitoring Strategies for A-VEGF Treated Age-Related Macular Degeneration: An Evidence-Based Analysis Optical Coherence Tomography Monitoring Strategies for A-VEGF Treated Age-Related Macular Degeneration: An Evidence-Based Analysis G Pron August 2014 Ontario Health Technology Assessment Series; Vol. 14:

More information

DOME SHAPED MACULOPATHY. Ιωάννης Ν. Βαγγελόπουλος Χειρ. Οφθαλμίατρος - Βόλος

DOME SHAPED MACULOPATHY. Ιωάννης Ν. Βαγγελόπουλος Χειρ. Οφθαλμίατρος - Βόλος DOME SHAPED MACULOPATHY Ιωάννης Ν. Βαγγελόπουλος Χειρ. Οφθαλμίατρος - Βόλος DOME SHAPED MACULOPATHY-DEFINITIONS The entity Dome Shaped Macula ( DSM ) was first described by Gaucher and associates in 2008

More information

An atypical case of choroidal neovascularization associated with pseudoxanthoma elasticum treated with intravitreal bevacizumab: a case report

An atypical case of choroidal neovascularization associated with pseudoxanthoma elasticum treated with intravitreal bevacizumab: a case report Karampelas et al. BMC Research Notes 2013, 6:530 CASE REPORT Open Access An atypical case of choroidal neovascularization associated with pseudoxanthoma elasticum treated with intravitreal bevacizumab:

More information

VERTEPORFIN IN PHOTODYNAMIC THERAPY STUDY GROUP

VERTEPORFIN IN PHOTODYNAMIC THERAPY STUDY GROUP Verteporfin Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration: Two-year Results of a Randomized Clinical Trial Including Lesions With Occult With No Classic Choroidal

More information

Angiogenesis and Role of Anti-VEGF Therapy

Angiogenesis and Role of Anti-VEGF Therapy Review Article Angiogenesis and Role of Anti-VEGF Therapy P.S. Mahar, Azfar N. Hanfi, Aimal Khan Pak J Ophthalmol 2009, Vol. 25 No. 3.....................................................................................................

More information

THE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION

THE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION THE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION MOESTIDJAB DEPARTMENT OF OPHTHALMOLOGY SCHOOL OF MEDICINE AIRLANGGA UNIVERSITY DR SOETOMO HOSPITAL SURABAYA INTRODUCTION

More information

ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR

ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THE ROLE OF RANIBIZUMAB * Michael L. Klein, MD ABSTRACT The positive 1-year results of ranibizumab trials reported at the 23rd Annual Meeting of the American Society of Retina Specialists have generated

More information

The limited number of currently approved

The limited number of currently approved CLINICAL TRIALS OF VERTEPORFIN AND PEGAPTANIB: WHAT ARE THE RESULTS? * William F. Mieler, MD ABSTRACT Currently available treatment options for the management of choroidal neovascularization (CNV) in age-related

More information

Clinical Study Choroidal Thickness in Eyes with Unilateral Ocular Ischemic Syndrome

Clinical Study Choroidal Thickness in Eyes with Unilateral Ocular Ischemic Syndrome Hindawi Publishing Corporation Journal of Ophthalmology Volume 215, Article ID 62372, 5 pages http://dx.doi.org/1.1155/215/62372 Clinical Study Choroidal Thickness in Eyes with Unilateral Ocular Ischemic

More information

Optical Coherence Tomography in Diabetic Retinopathy. Mrs Samantha Mann Consultant Ophthalmologist Clinical Lead of SEL-DESP

Optical Coherence Tomography in Diabetic Retinopathy. Mrs Samantha Mann Consultant Ophthalmologist Clinical Lead of SEL-DESP Optical Coherence Tomography in Diabetic Retinopathy Mrs Samantha Mann Consultant Ophthalmologist Clinical Lead of SEL-DESP Content OCT imaging Retinal layers OCT features in Diabetes Some NON DR features

More information

Noninvasive cross-sectional imaging of the retina

Noninvasive cross-sectional imaging of the retina IDENTIFICATION OF FLUID ON OPTICAL COHERENCE TOMOGRAPHY BY TREATING OPHTHALMOLOGISTS VERSUS A READING CENTER IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS CYNTHIA A. TOTH, MD,*

More information

Ranibizumab and pegaptanib for the treatment of agerelated macular degeneration

Ranibizumab and pegaptanib for the treatment of agerelated macular degeneration Ranibizumab and pegaptanib for the treatment of agerelated Issued: August 2008 last modified: May 2012 guidance.nice.org.uk/ta155 NHS Evidence has accredited the process used by the Centre for Health Technology

More information

Combined treatment for Coats disease: retinal laser photocoagulation combined with intravitreal bevacizumab injection was effective in two cases

Combined treatment for Coats disease: retinal laser photocoagulation combined with intravitreal bevacizumab injection was effective in two cases Kodama et al. BMC Ophthalmology 2014, 14:36 CASE REPORT Open Access Combined treatment for Coats disease: retinal laser photocoagulation combined with intravitreal bevacizumab injection was effective in

More information

Corinne GONZALEZ Ophthalmology (MD, Ph.D ) Retinal Medical Specialist

Corinne GONZALEZ Ophthalmology (MD, Ph.D ) Retinal Medical Specialist Corinne GONZALEZ Ophthalmology (MD, Ph.D ) Retinal Medical Specialist PRESENT PROFESSIONAL POSITION OPHTALMOLOGIST DOCTOR, Private practice Retinal medical Specialist, DMLA in particular Installation year

More information

Choroidal neovascularization (CNV) secondary to age-related

Choroidal neovascularization (CNV) secondary to age-related Retina Multifocal Pupillography Identifies Ranibizumab-Induced Changes in Retinal Function for Exudative Age-Related Macular Degeneration Faran Sabeti, 1 Ted Maddess, 1 Rohan W. Essex, 1,2 and Andrew C.

More information

Can intravitreal tissue plasminogen activator and SF6 gas facilitate management of macular degeneration with photodynamic therapy?

Can intravitreal tissue plasminogen activator and SF6 gas facilitate management of macular degeneration with photodynamic therapy? European Journal of Ophthalmology / Vol. 18 no. 4, 2008 / pp. 591-594 Can intravitreal tissue plasminogen activator and SF6 gas facilitate management of macular degeneration with photodynamic therapy?

More information

AGE-RELATED MACULAR DEGENERATION IS THE LEADing

AGE-RELATED MACULAR DEGENERATION IS THE LEADing Photodynamic Therapy for Age-related Macular Degeneration in a Clinical Setting: Visual Results and Angiographic Patterns RUTH AXER-SIEGEL, MD, RITA EHRLICH, MD, YUVAL YASSUR, MD, IRIT ROSENBLATT, MD,

More information

OCT Assessment of the Vitreoretinal Relationship in CSME

OCT Assessment of the Vitreoretinal Relationship in CSME December 2007 Sonia Rani John et al. - IFIS 375 ORIGINAL ARTICLE OCT Assessment of the Vitreoretinal Relationship in CSME Dr. Manoj S. DNB FRCS, Dr. Unnikrishnan Nair MS DO FRCS, Dr. Gargi Sathish MS Introduction

More information

Optical Coherence Tomography: Pearls for the Anterior Segment Surgeon Basic Science Michael Stewart, M.D.

Optical Coherence Tomography: Pearls for the Anterior Segment Surgeon Basic Science Michael Stewart, M.D. Optical Coherence Tomography: Pearls for the Anterior Segment Surgeon Basic Science Michael Stewart, M.D. Disclosure OCT Optical Coherence Tomography No relevant financial relationships I will refer to

More information

Long-term Management of AMD. Motasem Al-latayfeh, MD Assistant Prof. Ophthalmology Hashemite University Jordan

Long-term Management of AMD. Motasem Al-latayfeh, MD Assistant Prof. Ophthalmology Hashemite University Jordan Long-term Management of AMD Motasem Al-latayfeh, MD Assistant Prof. Ophthalmology Hashemite University Jordan DEFINITION 1 Age-related macular degeneration (AMD) is a disorder of the macula characterized

More information

I n the Western world, age related macular degeneration

I n the Western world, age related macular degeneration 207 SCIENTIFIC REPORT Clinicopathological findings of choroidal neovascularisation following verteporfin photodynamic therapy F Gelisken, B A Lafaut, W Inhoffen, M Voelker, S Grisanti, K U Bartz-Schmidt...

More information

Prevention and treatment of agerelated macular degeneration

Prevention and treatment of agerelated macular degeneration THERAPY REVIEW Prevention and treatment of agerelated macular degeneration SARAH HORTON AND CATHERINE GULY Age-related macular degeneration (AMD) is a common cause of visual loss in older people and GPs

More information

Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration

Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration and for Treatment of Neovascular Age-related Macular Degeneration Two-Year Results Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group* Writing Committee: Daniel F. Martin,

More information

Measurement of Subfoveal Choroidal Thickness Using Spectral Domain Optical Coherence Tomography

Measurement of Subfoveal Choroidal Thickness Using Spectral Domain Optical Coherence Tomography c l i n i c a l s c i e n c e Measurement of Subfoveal Choroidal Thickness Using Spectral Domain Optical Coherence Tomography Emily A. McCourt, MD; Brian C. Cadena, PhD; Cullen J. Barnett, CRA; Antonio

More information

The effect of intravitreal bevacizumab in a rare case of retinal dystrophy with secondary cystoid macular edema

The effect of intravitreal bevacizumab in a rare case of retinal dystrophy with secondary cystoid macular edema Romanian Journal of Ophthalmology, Volume 61, Issue 2, April-June 2017. pp:123-127 CASE REPORT The effect of intravitreal bevacizumab in a rare case of retinal dystrophy with secondary cystoid macular

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Retinal Complications of Obstructive Sleep Apnea A Growing Concern!

Retinal Complications of Obstructive Sleep Apnea A Growing Concern! Retinal Complications of Obstructive Sleep Apnea A Growing Concern! Jay M. Haynie, OD, FAAO Financial Disclosure I have received honoraria or am on the advisory board for the following companies: Carl

More information

FEP Medical Policy Manual

FEP Medical Policy Manual FEP Medical Policy Manual Last Review: September 2016 Next Review: September 2017 Related Policies 6.01.10 Stereotactic Radiosurgery and Stereotactic Body Radiotherapy 8.01.10 Charged-Particle (Proton

More information

OCT Angiography in Primary Eye Care

OCT Angiography in Primary Eye Care OCT Angiography in Primary Eye Care An Image Interpretation Primer Julie Rodman, OD, MS, FAAO and Nadia Waheed, MD, MPH Table of Contents Diabetic Retinopathy 3-6 Choroidal Neovascularization 7-9 Central

More information

Efficacy of Intravitreal Bevacizumab in Treatment of Proliferative Type 2 Idiopathic Juxtafoveal Telangiectasia

Efficacy of Intravitreal Bevacizumab in Treatment of Proliferative Type 2 Idiopathic Juxtafoveal Telangiectasia DOI: 10.4274/tjo.04874 Turk J Ophthalmol 2017;47:144-148 Original Article Efficacy of Intravitreal Bevacizumab in Treatment of Proliferative Type 2 Idiopathic Juxtafoveal Telangiectasia Ökkeş Baz, İhsan

More information

Clinical Study Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration

Clinical Study Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration Ophthalmology Volume 12, Article ID 69641, 8 pages doi:1.1155/12/69641 Clinical Study Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular

More information

Authors. Introduction. Introduction. Materials and Methods. Objective 10/27/2015

Authors. Introduction. Introduction. Materials and Methods. Objective 10/27/2015 Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) in Thai Population Presenting with Choroidal Neovascularization (CNV) A multicenter study Authors Yonrawee Piyacomn 1, Chavakij Bhoomibunchoo 1, Yosanan

More information

evaluation of vitreoretinal adhesions in exudative AMD using optical coherence tomography

evaluation of vitreoretinal adhesions in exudative AMD using optical coherence tomography evaluation of vitreoretinal adhesions in exudative AMD using optical coherence tomography Dr. Mahmoud Alaa Abouhusssein, FRCO Lecturer of ophthalmology, Alexandria university Dr. Amir Ramadan Gomaa, MD

More information

Intraocular Radiation Therapy for Age-Related Macular Degeneration

Intraocular Radiation Therapy for Age-Related Macular Degeneration Intraocular Radiation Therapy for Age-Related Macular Degeneration Policy Number: 9.03.20 Last Review: 9/2014 Origination: 9/2008 Next Review: 9/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue

More information

A Comparative Study of Age Related Macular Degeneration In Relation To SD-OCTand Fundus Photography.

A Comparative Study of Age Related Macular Degeneration In Relation To SD-OCTand Fundus Photography. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 14, Issue 11 Ver. III (Nov. 2015), PP 33-37 www.iosrjournals.org A Comparative Study of Age Related Macular

More information

TESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN)

TESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN) TESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN) ROBERTA P. A. MANZANO, MD, GHOLAM A. PEYMAN, MD, PALWASHA KHAN, MD, MUHAMET KIVILCIM, MD Purpose: To evaluate the retinal toxicity of varying doses

More information

MEDICAL POLICY SUBJECT: PHOTODYNAMIC THERAPY FOR EFFECTIVE DATE: 07/20/00 SUBFOVEAL CHOROIDAL NEOVASCULARIZATION

MEDICAL POLICY SUBJECT: PHOTODYNAMIC THERAPY FOR EFFECTIVE DATE: 07/20/00 SUBFOVEAL CHOROIDAL NEOVASCULARIZATION MEDICAL POLICY SUBJECT: PHOTODYNAMIC THERAPY FOR PAGE: 1 OF: 8 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including

More information